@article{Nishimura_A-2022_100841,
title = {International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients},
author = {Nishimura, A. and Xie, J. and Kostka, K. and Duarte-Salles, T. and Fernández Bertolín, S. and Aragón, M. and Blacketer, C. and Shoaibi, A. and DuVall, S. and Lynch, K. and Matheny, M. and Falconer, T. and Morales, D. and Conover, M. and Chan You, S. and Pratt, N. and Weaver, J. and Sena, A. and Schuemie, M. and Reps, J. and Reich, C. and Rijnbeek, P. and Ryan, P. and Hripcsak, G. and Prieto-Alhambra, D. and Suchard, M.},
month = {sep},
year = {2022},
abstract = {Purpose: Alpha-1 blockers, often used to treat benign prostatic hyperplasia (BPH), have been hypothesized to prevent COVID-19 complications by minimising cytokine storm release. The proposed treatment based on this hypothesis currently lacks support from reliable real-world evidence, however. We leverage an international network of large-scale healthcare databases to generate comprehensive evidence in a transparent and reproducible manner.},
volume = {13},
journal = {Frontiers in Pharmacology},
publisher = {Frontiers Media},
url = {https://doi.org/10.3389/fphar.2022.945592},
}
